The French government has secured a stake in Sanofi's Opella subsidiary, which markets Doliprane, in order to protect the production of essential medicines.

The agreement includes guarantees to maintain and develop operations in France, with the government acquiring a minority stake through the public investment bank Bpifrance. Sanofi will retain a significant shareholding, while Clayton, Dubilier & Rice (CD&R) will acquire a 50% controlling interest.

The deal aims to ensure the security of supply for Doliprane and other critical medications in France. The government has outlined stringent conditions, including a commitment to produce 250 million boxes of Doliprane annually in France, and has imposed substantial penalties for non-compliance.

CD&R has committed to investing 70 million euros over the next five years to support the growth of Opella. The collaboration between CD&R and Bpifrance aims to create a stable environment for the production of essential medicines and foster innovation in the healthcare sector.

The government has reassured the public that it is committed to safeguarding jobs and ensuring a secure supply of medicines, and by acquiring a stake in Opella, it aims to play an active role in its governance.

This agreement is significant for the French pharmaceutical industry as it balances the interests of private investors with the public's need for essential healthcare products.